US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

44.91

+0.24000.54%

Post-market: 44.910.00000.00%16:13 EDT

Volume:1.51M

Turnover:67.84M

Market Cap:286.12B

PE:28.96

High:45.21

Open:44.55

Low:44.50

Close:44.67

52wk High:45.94

52wk Low:34.10

Shares:6.37B

Float Shares:6.37B

Volume Ratio:1.11

T/O Rate:0.02%

Dividend:1.53

Dividend Rate:3.40%

EPS(TTM):1.55

EPS(LYR):2.14

ROE:31.32%

ROA:13.30%

PB:7.92

PE(LYR):21.02

Loading ...

Overview Company News Filings

Starpharma enters collaboration, license agreement with Genentech

Roche Holding Ltd (RHHBY.US) to Advance Weight Loss Drug CT-388 to Late-Stage Trials Next Year, Challenging Eli Lilly and Novo-Nordisk A/S Dominance

Roche Holding Ltd (RHHBY.US) Breast Cancer Drug Meets Primary Endpoint in Phase III Trial, Extending Progression-Free Survival in Advanced Patients

Roche achieves CLIA ‘Moderate Complexity’ categorization for Ionify assay

89bio Stock Soars 83% as Roche to Acquire the Liver Drug Developer for up to $3.5 Billion

Roche Holding Ltd to Acquire 89Bio, Inc. for Up to $3.5 Billion, Strengthening Position in Weight Loss Drug Market

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D -- Barrons.com

Roche receives CE Mark for Accu-Check SmartGuide CGM solution

Roche Holding AG Falls Tuesday, Outperforms Market

Roche Holding AG Rises Wednesday, Outperforms Market

Roche Holding Ltd (RHHBY.US) Invests $400 Million in IBD Sector with Preclinical Oral Small Molecule Development

Roche Holding AG Flat Monday, Outperforms Market

Roche, Alnylam Move Hypertension Drug to Late-Stage Trial

Roche Holding AG Falls Friday

Roche Holding AG Rises Wednesday, Outperforms Market

Roche's Genentech Breaks Ground on North Carolina Manufacturing Site

Swiss Pharma Stocks Price in Potential Hit From Trump Policies -- Market Talk

Roche Holding AG Flat Monday

Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement

Roche Holding AG Rises Wednesday, Outperforms Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":44.91,"timestamp":1760731200000,"preClose":44.67,"halted":0,"volume":1508399,"hourTrading":{"tag":"盘后","latestPrice":44.91,"preClose":44.91,"latestTime":"16:13 EDT","volume":2124,"amount":95577.23999999999,"timestamp":1760732012878},"delay":15,"floatShares":6371000000,"shares":6371000000,"eps":1.550894,"marketStatus":"Market Closed","change":0.24,"latestTime":"10-17 16:00:00 EDT Delay","open":44.55,"high":45.21,"low":44.5,"amount":67842077.70110008,"amplitude":0.015894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":44.67,"volumeRatio":1.1074856506858959},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6371000000,"roa":"13.30%","roe":"31.32%","lyrEps":2.136203,"volumeRatio":1.1074856506858959,"shares":6371000000,"dividePrice":1.528373,"high":45.21,"amplitude":0.015894,"preClose":44.67,"low":44.5,"week52Low":34.103,"pbRate":"7.92","psRate":"3.58","week52High":45.94,"institutionHeld":0.0396,"latestPrice":44.91,"eps":1.550894,"divideRate":0.034032,"volume":1508399,"delay":15,"ttmEps":1.550894,"open":44.55,"prevYearClose":34.88,"prevWeekClose":45.66,"prevMonthClose":41.81,"prevQuarterClose":41.81,"fiveDayClose":45.66,"twentyDayClose":41.79,"sixtyDayClose":41.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.375,"hold":0.375,"sell":0.125,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1759636800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2569781665","title":"Starpharma enters collaboration, license agreement with Genentech","url":"https://stock-news.laohu8.com/highlight/detail?id=2569781665","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569781665?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:40","pubTimestamp":1758541251,"startTime":"0","endTime":"0","summary":"Starpharma (SPHRY) announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group (RHHBY), to develop p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/starpharma-enters-collaboration-license-agreement-with-genentech-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/starpharma-enters-collaboration-license-agreement-with-genentech-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","SPHRY","BK4007"],"gpt_icon":0},{"id":"1118663807","title":"Roche Holding Ltd (RHHBY.US) to Advance Weight Loss Drug CT-388 to Late-Stage Trials Next Year, Challenging Eli Lilly and Novo-Nordisk A/S Dominance","url":"https://stock-news.laohu8.com/highlight/detail?id=1118663807","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118663807?lang=en_us&edition=fundamental","pubTime":"2025-09-22 17:32","pubTimestamp":1758533551,"startTime":"0","endTime":"0","summary":"Roche Holding Ltd (RHHBY.US) plans to advance its experimental weight loss drug CT-388 to late-stage clinical trials next year, aiming to challenge market leaders Eli Lilly (LLY.US) and Novo-Nordisk...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c8c015636e69da2c01039595706c31dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU0354030438.USD","LU1868836757.USD","SG9999018865.SGD","LU2360106947.USD","LU0882574139.USD","SG9999014906.USD","LU2089984988.USD","LLY","LU1720051108.HKD","LU2237443978.SGD","LU2552382058.USD","LU0320765992.SGD","SG9999015986.USD","LU2491050071.SGD","LU2456880835.USD","LU2357305700.SGD","LU0203201768.USD","IE0009355771.USD","LU0471298694.HKD","LU0820561818.USD","LU0234572021.USD","LU0823434740.USD","LU0256863811.USD","LU2265009873.SGD","LU0094547139.USD","LU0471298777.SGD","LU0320765059.SGD","LU0672654240.SGD","SGXZ31699556.SGD","LU1917777945.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0689472784.USD","LU0289739699.SGD","SG9999018857.SGD","LU2063271972.USD","LU0823416689.USD","LU2237443549.SGD","LU0823434583.USD","LU0432979614.USD","LU2236285917.USD","LU2264538146.SGD","LU2491050154.USD","IE00B1BXHZ80.USD","LU0385154629.USD","LU1366192091.USD","LU0106261372.USD","IE0004445239.USD","LU1720051017.SGD","SGXZ51526630.SGD","LU1989771016.USD","LU1804176565.USD","LU2361044865.SGD","LU0238689110.USD","LU1061106388.HKD","LU1868836591.USD","BK4534","NVO","LU1868837136.USD","LU2461242641.AUD","BK4532","LU2750360641.GBP","LU2237443382.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0466842654.USD","LU2112291526.USD","LU2552382132.HKD","SG9999001176.SGD","LU0353189680.USD","LU0058720904.USD","LU0316494557.USD","LU0323591593.USD","BK4588","LU1868837300.USD","LU1127390331.HKD","SG9999014880.SGD","GB00BDT5M118.USD","LU1093756168.USD","SG9999015945.SGD","LU0820561909.HKD","SGXZ99366536.SGD","IE00BK4W5M84.HKD","LU0006306889.USD","03165","LU1814569148.SGD","BK4007","LU0109394709.USD","LU2746668974.SGD","LU1974910355.USD","LU2324357040.USD","LU0256863902.USD","LU0786609619.USD","LU2106854487.HKD","LU2552382215.SGD","LU2471134952.CNY","IE00BJJMRZ35.SGD","LU2471134796.USD","LU2237443622.USD","SG9999014914.USD","LU1988902786.USD","LU1623119135.USD","LU1023059063.AUD","BK4516","BK4533","LU0154236417.USD","LU0708995401.HKD","LU2361045086.USD","LU0417517546.SGD","SG9999015952.SGD","LU1035775433.USD","IE00BKVL7J92.USD","BK4585","SG9999017495.SGD","LU0882574055.USD","IE00BK4W5L77.USD","IE00B4R5TH58.HKD","LU2491049909.HKD","LU0266013472.USD","LU2108987350.USD","SG9999001176.USD","SG9999015978.USD","LU1551013342.USD","LU2087625088.SGD","BK4599","SGXZ57979304.SGD","LU0198837287.USD","LU1232071149.USD","LU0096364046.USD","LU2468319806.SGD","LU2211815571.USD","BK4581","SGXZ81514606.USD","LU0203202063.USD","LU2602419157.SGD","LU1291159041.SGD","LU2417539215.USD","LU2023250504.SGD","LU1064131342.USD","LU1551013425.SGD","LU1069344957.HKD","IE00BFTCPJ56.SGD","LU0353189763.USD","SG9999014898.SGD","LU2237443895.HKD","LU0109391861.USD","LU1280957306.USD","LU2746668461.USD","RHHBY","LU1267930730.SGD","LU2361044949.HKD","LU0061475181.USD","LU0097036916.USD","LU0943347566.SGD","LU1057294990.SGD","LU2471134523.USD","LU2471134879.HKD","IE0002141913.USD","LU1548497426.USD","LU0889565916.HKD","LU1712237335.SGD","SG9999013999.USD","IE00BJLML261.HKD","LU2462157665.USD","LU1983299246.USD","LU0079474960.USD","LU2237443465.HKD","LU0354030511.USD","LU0456855351.SGD","LU2750360997.AUD","LU0122379950.USD","LU1868836914.USD","IE00BZ1G4Q59.USD","LU0640476718.USD"],"gpt_icon":1},{"id":"1157084803","title":"Roche Holding Ltd (RHHBY.US) Breast Cancer Drug Meets Primary Endpoint in Phase III Trial, Extending Progression-Free Survival in Advanced Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1157084803","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157084803?lang=en_us&edition=fundamental","pubTime":"2025-09-22 17:32","pubTimestamp":1758533551,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical company Roche Holding Ltd (RHHBY.US) announced positive results from the Phase III evERA study of Giredestrant for breast cancer treatment. Giredestrant helped extend disease...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2568040584","title":"Roche achieves CLIA ‘Moderate Complexity’ categorization for Ionify assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2568040584","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568040584?lang=en_us&edition=fundamental","pubTime":"2025-09-18 22:05","pubTimestamp":1758204321,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the U.S. Food and Drug Administration has categorized its Ionify 25-Hydroxy Vitamin D total assay as “Moderate Complex...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-achieves-clia-moderate-complexity-categorization-for-ionify-assay-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-achieves-clia-moderate-complexity-categorization-for-ionify-assay-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLIA","BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2568423396","title":"89bio Stock Soars 83% as Roche to Acquire the Liver Drug Developer for up to $3.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2568423396","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568423396?lang=en_us&edition=fundamental","pubTime":"2025-09-18 16:57","pubTimestamp":1758185851,"startTime":"0","endTime":"0","summary":"Roche has agreed to buy U.S. biotech firm $89Bio, Inc.(ETNB) for up to $3.5 billion to strengthen its development pipeline of liver and cardiometabolic disease treatments, the Swiss drugmaker said on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"720d08cdcd6a785ff31d49645aa5188d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nL5N3V503X:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche to Acquire Liver Drug Developer 89bio for up to $3.5 Billion","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETNB","RHHBY"],"gpt_icon":0},{"id":"1127477924","title":"Roche Holding Ltd to Acquire 89Bio, Inc. for Up to $3.5 Billion, Strengthening Position in Weight Loss Drug Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1127477924","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127477924?lang=en_us&edition=fundamental","pubTime":"2025-09-18 15:38","pubTimestamp":1758181112,"startTime":"0","endTime":"0","summary":"Roche Holding Ltd (RHHBY.US) will acquire biotech company 89Bio, Inc. (ETNB.US) for up to $3.5 billion, marking the Swiss pharmaceutical giant's latest strategic move into the weight loss drug and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"720d08cdcd6a785ff31d49645aa5188d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ETNB","RHHBY","BK4585","03165"],"gpt_icon":0},{"id":"2568743481","title":"GSK Says It Will Spend $30B on U.S. Manufacturing and R&D -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2568743481","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568743481?lang=en_us&edition=fundamental","pubTime":"2025-09-17 07:01","pubTimestamp":1758063660,"startTime":"0","endTime":"0","summary":"The U.K.-based drugmaker GSK said late Tuesday that it plans to invest $30 billion over the next five years in the U.S., making it the latest drugmaker promising big spending on U.S. infrastructure.President Donald Trump has made expanding domestic manufacturing a priority in his second term, while threatening tariffs as high as 200% on pharmaceutical imports. Drugmakers, in response, have been scrambling to plan multibillion-dollar investments in their U.S. operations.GSK offered few details on the $30 billion headline number in its Tuesday press release. Its statement detailed plans for a $1.2 billion investment that would include construction of a manufacturing factory in Pennsylvania, set to begin next year, along with new AI capabilities to existing GSK manufacturing sites in the U.S.Drugmakers like GSK have found themselves at the center of multiple Trump administration proposals, as the president and his allies have pushed for lower drug prices, higher drug tariffs, and limits o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","LU2129689514.USD","LU1868837300.USD","LU2324357040.USD","IE00BLSP4239.USD","LU1674673428.USD","LU0203201768.USD","BK4599","IE00B3T34201.USD","RHHBY","GSK","LU1914381329.SGD","LU0792757196.USD","LU0640476718.USD","LU1868836757.USD","SG9999013999.USD","LU2129689605.HKD","AZN","IE00BJLML261.HKD","LU1983299246.USD","LU2505996509.AUD","LU0203202063.USD","LU2237443978.SGD","LU1989771016.USD","LU1059921491.USD","LU0256863811.USD","GSK.UK","LU1674673691.USD","LU1894683264.USD","LU2456880835.USD","LU0354030511.USD","LU1868836591.USD","03165","LU2360106947.USD","IE00B19Z3B42.SGD","LU1868837136.USD","LU2430703178.SGD","IE0002141913.USD","LU0096364046.USD","LU0985320562.USD","LU2430703251.USD","LU1066053197.SGD","LU1069344957.HKD","LU1093756325.SGD","IE00BLSP4452.SGD","IE00BJJMRZ35.SGD","LU2505996681.GBP","LU1061106388.HKD","LU0354030438.USD"],"gpt_icon":1},{"id":"2567648572","title":"Roche receives CE Mark for Accu-Check SmartGuide CGM solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2567648572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567648572?lang=en_us&edition=fundamental","pubTime":"2025-09-16 22:05","pubTimestamp":1758031523,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) said it shared real-world evidence from the rollout of Accu-Chek SmartGuide continuous glucose monitoring solution at the European As...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-ce-mark-for-accu-check-smartguide-cgm-solution-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-ce-mark-for-accu-check-smartguide-cgm-solution-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","RHHBY","03165","BK4109","BK4007","CE","BK4588"],"gpt_icon":0},{"id":"2566361159","title":"Roche Holding AG Falls Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2566361159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566361159?lang=en_us&edition=fundamental","pubTime":"2025-09-10 00:17","pubTimestamp":1757434620,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  slid 0.1% to CHF269.70 Tuesday on what proved to be an overall unfavorable trading session for the stock market, with the   falling 0.3% to 12,281.09.This was the stock's third consecutive day of losses.Roche Holding AG closed CHF44.10 below its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 593,881, compared to the 50-day average trading volume of 892,346.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2564390599","title":"Roche Holding AG Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2564390599","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564390599?lang=en_us&edition=fundamental","pubTime":"2025-09-04 00:17","pubTimestamp":1756916220,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 2.9% to CHF269.50 Wednesday on what proved to be an overall positive trading session for the stock market, with the   rising 0.9% to 12,200.00.This was the stock's second consecutive day of gains.Roche Holding AG closed CHF44.30 below its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 1,938,701, compared to the 50-day average trading volume of 858,139.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"1190131189","title":"Roche Holding Ltd (RHHBY.US) Invests $400 Million in IBD Sector with Preclinical Oral Small Molecule Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1190131189","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190131189?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:18","pubTimestamp":1756819100,"startTime":"0","endTime":"0","summary":"On September 2nd, OMass Therapeutics announced it has entered into an exclusive collaboration and licensing agreement with Genentech, a member of the Roche Holding Ltd (RHHBY.US) group, granting the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","IBD","03165","BK4007"],"gpt_icon":0},{"id":"2564465668","title":"Roche Holding AG Flat Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2564465668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564465668?lang=en_us&edition=fundamental","pubTime":"2025-09-02 00:17","pubTimestamp":1756743420,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  were flat  at CHF260.20 Monday on what proved to be an overall poor trading session for the stock market, with the   falling 0.1% to 12,176.52.This was the stock's third consecutive day of losses.Roche Holding AG closed CHF53.60 short of its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 896,093, compared to the 50-day average trading volume of 943,346.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2564896571","title":"Roche, Alnylam Move Hypertension Drug to Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2564896571","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564896571?lang=en_us&edition=fundamental","pubTime":"2025-09-01 14:08","pubTimestamp":1756706880,"startTime":"0","endTime":"0","summary":"Roche Holding and Alnylam Pharmaceuticals said they decided to move experimental hypertension drug zilebesiran to a late-stage trial after results from mid-stage studies showed mixed results.The pharmaceutical companies said Saturday that the third phase of a mid-stage trial for zilebesiran in patients with uncontrolled hypertension and high cardiovascular risk showed reductions in systolic blood pressure at the third month of treatment that were sustained out to the sixth month. However, the study didn't reach a level the companies considered statistically significant.The study did achieve the aim of identifying the patient population that could potentially benefit the most from zilebesiran, Roche and Alnylam said.The companies said their decision to advance to a late-stage trial was based on the whole mid-stage program, which included two previous studies that met their main objectives. The trial is due to start by the end of the year, they said.Zilebesiran is a twice-yearly therapy ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","SSI","BK4007","LU0109394709.USD","BK4585","LU0320765992.SGD","03165","BK4139","LU0889565916.HKD","ALNY","BK4588","BK4548"],"gpt_icon":0},{"id":"2563786730","title":"Roche Holding AG Falls Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2563786730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563786730?lang=en_us&edition=fundamental","pubTime":"2025-08-30 00:17","pubTimestamp":1756484220,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  dropped 0.3% to CHF260.30 Friday on what proved to be an overall poor trading session for the stock market, with the   falling 0.3% to 12,187.58.This was the stock's second consecutive day of losses.Roche Holding AG closed CHF53.50 short of its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 761,160, compared to the 50-day average trading volume of 942,452.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4210","AG","BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2562422725","title":"Roche Holding AG Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2562422725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562422725?lang=en_us&edition=fundamental","pubTime":"2025-08-28 00:17","pubTimestamp":1756311420,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 1.3% to CHF262.60 Wednesday on what proved to be an overall favorable trading session for the stock market, with the   rising 0.4% to 12,207.12.The stock's rise snapped a three-day losing streak.Roche Holding AG closed CHF51.20 short of its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 1,429,846, compared to the 50-day average trading volume of 935,365.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2562922478","title":"Roche's Genentech Breaks Ground on North Carolina Manufacturing Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2562922478","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562922478?lang=en_us&edition=fundamental","pubTime":"2025-08-26 02:58","pubTimestamp":1756148280,"startTime":"0","endTime":"0","summary":"Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina.The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast.The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said.The facility is scheduled to be completed and operational by 2029.The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARO","RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2561756406","title":"Swiss Pharma Stocks Price in Potential Hit From Trump Policies -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2561756406","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561756406?lang=en_us&edition=fundamental","pubTime":"2025-08-23 00:03","pubTimestamp":1755878580,"startTime":"0","endTime":"0","summary":"1603 GMT - The results of a U.S. probe into the pharmaceutical sector are imminent, but any potential hits from President Trump's tariffs and drug-price policies seem to be already priced in by Swiss pharma stocks, Vontobel's Stefan Schneider says in a note. Vontobel estimates U.S. drug prices could be cut by between 5% and 33%, but finds that this is already factored into Swiss pharma stock prices. According to Vontobel's analysis, Roche shares could see a movement from 0% in its base-case scenario to a 7% drop in its worst-case scenario, while Novartis shares could either rise or fall by 8%. This means the outcome of the U.S. investigation could also trigger share-price rises as a clearer picture emerges, the analyst says. Shares in Novartis and Roche close 0.9% and 0.4% lower, respectively. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0070302665.USD","BK4578","LU0320765489.SGD","RHHBY","IE00B2B36J28.USD","LU0208291251.USD","IE0002141913.USD","03165","BK4585","BK4007","BK4588","BK4532","LU0211331839.USD","NVS"],"gpt_icon":0},{"id":"2560810751","title":"Roche Holding AG Flat Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2560810751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560810751?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:17","pubTimestamp":1755533820,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  were flat  at CHF256.00 Monday on what proved to be an overall mediocre trading session for the stock market, with the   holding steady at 12,071.88.Roche Holding AG closed CHF57.80 below its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 599,817, compared to the 50-day average trading volume of 947,467.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","03165","BK4007","BK4210","RHHBY"],"gpt_icon":0},{"id":"2560190018","title":"Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2560190018","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560190018?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:53","pubTimestamp":1755521580,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.Shares of Adaptive fall 1.7% in premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","RHHBY","03165","BK4121","BK4007"],"gpt_icon":0},{"id":"2559985624","title":"Roche Holding AG Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2559985624","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559985624?lang=en_us&edition=fundamental","pubTime":"2025-08-14 00:17","pubTimestamp":1755101820,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 1.3% to CHF249.70 Wednesday on what proved to be an overall positive trading session for the stock market, with the   rising 0.8% to 11,978.85.This was the stock's second consecutive day of gains.Roche Holding AG closed CHF64.10 short of its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 932,605, compared to the 50-day average trading volume of 917,304.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":82,"code":"91000000","status":"200"}]}}